iCo Therapeutics (iCo Therapeutics) Additional Paid-In Capital : $5.22 Mil(As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Additional Paid-In Capital?

iCo Therapeutics's quarterly additional paid-in capital increased from Sep. 2020 ($4.92 Mil) to Dec. 2020 ($5.11 Mil) and increased from Dec. 2020 ($5.11 Mil) to Mar. 2021 ($5.22 Mil).

iCo Therapeutics's annual additional paid-in capital increased from Dec. 2018 ($3.19 Mil) to Dec. 2019 ($4.90 Mil) and increased from Dec. 2019 ($4.90 Mil) to Dec. 2020 ($5.11 Mil).

iCo Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for iCo Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Additional Paid-In Capital Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Additional Paid-In Capital

Get a 7-Day Free Trial

23.66

2.76

3.19

4.90

5.11

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Additional Paid-In Capital	Get a 7-Day Free Trial															4.64	4.80	4.92	5.11	5.22

iCo Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

iCo Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines